The UK approved the Alzheimer's drug Kisunla, facing reimbursement challenges due to cost. NICE requires cost-effective benefits for NHS reimbursement. Kisunla targets beta amyloid and tau plaque in the brain, showing promise in slowing cognitive decline. Similar challenges were seen with Leqembi.